Advanced search
Publication Cover
Open Access Rheumatology: Research and Reviews Volume 13, 2021 - Issue
Submit an article Journal homepage
193
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Clinical Outcomes in Iraqi Patients with Rheumatoid Arthritis Following Earlier or Later Treatment with Etanercept

Nizar Al-Ani1 Rheumatology Unit, College of Medicine, University of Baghdad, Baghdad, IraqORCID Iconhttps://orcid.org/0000-0003-0659-8130View further author information
ORCID Icon,
Faiq Gorial1 Rheumatology Unit, College of Medicine, University of Baghdad, Baghdad, IraqView further author information
,
Dina Yasiry2 Department of Rheumatology, Baghdad Teaching Hospital, Baghdad, IraqView further author information
,
Fadya Al Derwibee2 Department of Rheumatology, Baghdad Teaching Hospital, Baghdad, IraqView further author information
,
Yasameen Abbas Humadi3 College of Medicine, Al-Nahrain University, Baghdad, IraqORCID Iconhttps://orcid.org/0000-0002-0911-8318View further author information
ORCID Icon,
Nancy Sunna4 Medical Department, Pfizer, Amman, JordanView further author information
&
Ali AlJabban5 Medical Department, Pfizer, Baghdad, IraqCorrespondence[email protected]
View further author information
 show all
Pages 57-62 | Published online: 19 Apr 2021

References

  • Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55(6):864–872. doi:10.1002/art.22353
  • Kyburz D, Gabay C, Michel BA, Finckh A. physicians of SCQM-RA. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort study. Rheumatology. 2011;50(6):1106–1110. doi:10.1093/rheumatology/keq424
  • van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(5):861–870. doi:10.1136/annrheumdis-2012-203130
  • Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–699. doi:10.1136/annrheumdis-2019-216655
  • Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10):578–582. doi:10.1038/nrrheum.2009.181
  • Almoallim HM, Alharbi LA. Rheumatoid arthritis in Saudi Arabia. Saudi Med J. 2014;35(12):1442–1454.
  • Al Saleh J, Ragab G, Nash P, et al. Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management? Clin Rheumatol. 2015;34(1):1–8. doi:10.1007/s10067-014-2818-5
  • Hussain W, Noorwali A, Janoudi N, et al. From symptoms to diagnosis: an observational study of the journey of rheumatoid arthritis patients in Saudi Arabia. Oman Med J. 2016;31(1):29–34. doi:10.5001/omj.2016.06
  • Hammoudeh M, Al Awadhi A, Hasan EH, Akhlaghi M, Ahmadzadeh A, Sadeghi Abdollahi B. Safety, tolerability, and efficacy of tocilizumab in rheumatoid arthritis: an open-label phase 4 study in patients from the Middle East. Int J Rheumatol. 2015;2015:975028. doi:10.1155/2015/975028

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.